Barclays’s Loxo Oncology, Inc LOXO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2019
Q1 | – | Sell |
-7,699
| Closed | -$1.08M | – | 7597 |
|
|
2018
Q4 | $1.08M | Sell |
7,699
-18,093
| -70% | -$2.75M | ﹤0.01% | 3043 |
|
|
2018
Q3 | $4.41M | Buy |
25,792
+19,082
| +284% | +$3.21M | ﹤0.01% | 1943 |
|
|
2018
Q2 | $1.16M | Sell |
6,710
-2,617
| -28% | -$393K | ﹤0.01% | 3116 |
|
|
2018
Q1 | $1.08M | Buy |
9,327
+3,554
| +62% | +$378K | ﹤0.01% | 3123 |
|
|
2017
Q4 | $485K | Buy |
5,773
+3,108
| +117% | +$259K | ﹤0.01% | 3863 |
|
|
2017
Q3 | $246K | Buy |
2,665
+1,124
| +73% | +$87.3K | ﹤0.01% | 4257 |
|
|
2017
Q2 | $123K | Sell |
1,541
-3,372
| -69% | -$187K | ﹤0.01% | 4766 |
|
|
2017
Q1 | $207K | Buy |
4,913
+429
| +10% | +$17.7K | ﹤0.01% | 4284 |
|
|
2016
Q4 | $144K | Buy |
4,484
+1,590
| +55% | +$40.8K | ﹤0.01% | 4482 |
|
|
2016
Q3 | $76K | Buy |
2,894
+230
| +9% | +$6.02K | ﹤0.01% | 4707 |
|
|
2016
Q2 | $62K | Buy |
+2,664
| New | +$66.3K | ﹤0.01% | 4724 |
|
|
2015
Q4 | – | Sell |
-40
| Closed | -$1K | – | 6922 |
|
|
2015
Q3 | $1K | Sell |
40
-110
| -73% | -$2.15K | ﹤0.01% | 6701 |
|
|
2015
Q2 | $3K | Buy |
150
+38
| +34% | +$519 | ﹤0.01% | 6732 |
|
|
2015
Q1 | $1K | Sell |
112
-94
| -46% | -$1.17K | ﹤0.01% | 7012 |
|
|
2014
Q4 | $2K | Buy |
+206
| New | +$2.4K | ﹤0.01% | 7144 |
|
Other funds holding LOXO
Barclays's LOXO Position: Q1 2019 in Review
Barclays sold out of Loxo Oncology, Inc (LOXO) in Q1 2019, closing a stake of 7,699 shares — an estimated $1.08M sold.
Barclays first reported a position in LOXO in Q4 2014 and held it in 15 quarters. The position peaked at $4.41M in Q3 2018. 1 fund tracked by Wall St. Rank holds LOXO as of Q1 2019.
- Barclays reported no remaining Loxo Oncology, Inc position as of Q1 2019 after selling out during the quarter.
- Barclays sold 7,699 Loxo Oncology, Inc shares in Q1 2019, an estimated $1.08M.
- Barclays first reported a position in Loxo Oncology, Inc in Q4 2014 and held it in 15 quarters.
- Barclays's Loxo Oncology, Inc position peaked at $4.41M in Q3 2018.
- 1 fund tracked by Wall St. Rank held Loxo Oncology, Inc as of Q1 2019.
Based on Barclays's 13F filing for Q1 2019, filed 15 May 2019.